恶性黑色素瘤肝转移瘤多柔比星洗脱微球化疗栓塞术中三维灌注测量的可行性研究
这项前瞻性II期试验纳入10例仅肝转移的黑色素瘤患者,在DEBDOX-TACE术前术后用CBCT新软件评估肿瘤灌注,并与MDCT对照。CBCT显示转移瘤灌注降低94.7%,MDCT显示96.8%,两种方法降低均具统计学显著性(p < 0.01)。CBCT灌注成像所需对比剂和辐射剂量均低于MDCT。
要点
- CBCT灌注软件可在DEBDOX-TACE术中评估黑色素瘤肝转移瘤灌注,术后灌注降低94.7%。
- MDCT对照显示灌注降低96.8%,两种方法降低均具统计学显著性(p < 0.01)。
- CBCT灌注成像对比剂18 ml、DLP 394 mGy*cm,均低于MDCT的100 ml和446 mGy*cm。
核心结论
- DEBDOX-TACE术后黑色素瘤转移瘤灌注降低可通过CBCT灌注软件在介入术中可靠评估,数据采集与分析需要额外时间但可在治疗过程中方便完成。
研究设计与样本
- 前瞻性II期试验,纳入10例仅肝转移的恶性黑色素瘤患者,行多柔比星洗脱微球化疗栓塞(DEBDOX-TACE),术前术后用CBCT新软件评估肿瘤灌注,并以增强MDCT作对照比较。
诊断标准与关键数值
- CBCT显示DEBDOX-TACE术后转移瘤灌注降低94.7%,MDCT显示降低96.8%,两种方法的灌注降低均具统计学显著性(p < 0.01)。
- CBCT灌注成像额外对比剂18 ml、DLP 394 mGy*cm;MDCT分别为100 ml和446 mGy*cm。
- 术中数据采集额外时间每例5分钟或更少,后处理数据分析10分钟或更少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To study feasibility and validity of a new software application for intraprocedural assessment of perfusion during chemoembolisation of melanoma metastases.
METHODOLOGY: In a prospective phase-II trial, ten melanoma patients with liver-only metastases underwent chemoembolisation with doxorubicin-eluting beads (DEBDOX-TACE). Tumour perfusion was evaluated immediately before and after treatment at cone beam computer tomography (CBCT) using a new software application. For control and comparison, patients underwent perfusion measurement via contrast-enhanced multidetector CT (MDCT) before and after treatment.
RESULTS: CBCT showed 94.7 % reduction in perfusion in metastases after DEBDOX-TACE, whereas MDCT showed 96.8 %. Reduction in perfusion after treatment was statistically significant (p < 0.01) for both methods. The additional time needed for data acquisition during treatment was 5 min per case or less; the post-processing data analysis was 10 min or less. Perfusion imaging was associated with additional contrast agent and patient exposure to radiation (dose-length product [DLP]): 18 ml and 394 mGy*cm in CBCT and 100 ml and 446 mGy*cm in MDCT, respectively.
CONCLUSIONS: Reduction in perfusion of melanoma metastases after DEBDOX-TACE can be reliably assessed during the intervention via perfusion software at CBCT. Data acquisition and analysis require additional time but can be easily performed during the treatment.
KEY POINTS: • Tumour perfusion of melanoma metastases can be assessed at cone beam CT. • The software shows a significant decrease of tumour perfusion after DEBDOX-TACE. • Data acquisition and analysis require an acceptable additional time during the procedure. • CBCT requires less radiation exposure and contrast for perfusion study than MSCT. • This software can monitor the course of DEBDOX-TACE in melanoma metastases.
引用
- Pereira PL, Krüger K, Hohenstein E, et al. Intraprocedural 3D perfusion measurement during chemoembolisation with doxorubicin-eluting beads in liver metastases of malignant melanoma. Eur Radiol. 2017. PMID: 29124381. doi:10.1007/s00330-017-5099-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。